Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis

Doi, Yohei; Shinzawa, Maki; Arisato, Tetsuya; Oka, Hideaki; Ueda, Yoshiyasu; Matsumoto, Ayumi; Kitamura, Harumi; Hamano, Takayuki; Nakazono, Yumi; Nishiya, Yoichi; Hashimoto, Nobuhiro; Matsuo, Miki; Sonoura, Takuryu; Monden, Chikako; Kamimura, Taro; Hayashi, Terumasa; Yoshihara, Fumiki; Isaka, Yoshitaka

doi:https://doi.org/10.1016/j.ekir.2025.09.049

Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis

Doi, Yohei; Shinzawa, Maki; Arisato, Tetsuya et al.

Kidney International Reports, 2025, 11(1), 141-151

アクセス数:76件（2026-02-16 00:39 集計）

固定URL: https://hdl.handle.net/11094/103674

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
KidneyIntlRep_11_1_141	pdf	なし	1.25 MB	13	2026.01.30

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis
著者	NRID 1000030846382 1000030846382 ORCID 0000-0002-5165-291X 0000-0002-5165-291X researchmap permalink DOI-YOHEI DOI-YOHEI Scopus Author ID 57204973692 57204973692 著者名 Doi, Yohei
	NRID 1000030704788 1000030704788 ORCID 0000-0002-7739-893X 0000-0002-7739-893X researchmap permalink 7000009447 7000009447 Scopus Author ID 47661817400 47661817400 著者名 Shinzawa, Maki
	NRID 1000050956456 1000050956456 著者名 Arisato, Tetsuya
	著者名 Oka, Hideaki
	著者名 Ueda, Yoshiyasu
	NRID 1000040794053 1000040794053 ORCID 0000-0002-2743-1439 0000-0002-2743-1439 Scopus Author ID 57200577037 57200577037 著者名 Matsumoto, Ayumi
	NRID 1000060570356 1000060570356 researchmap permalink kitamura3857 kitamura3857 Scopus Author ID 24334934300 24334934300 著者名 Kitamura, Harumi
	NRID 1000050403077 1000050403077 ORCID 0000-0002-2100-9106 0000-0002-2100-9106 researchmap permalink hamano-handai3857 hamano-handai3857 Scopus Author ID 8642906500 8642906500 著者名 Hamano, Takayuki
	著者名 Nakazono, Yumi
	著者名 Nishiya, Yoichi
	NRID 1000050791589 1000050791589 著者名 Hashimoto, Nobuhiro
	NRID 1000030956470 1000030956470 著者名 Matsuo, Miki
	著者名 Sonoura, Takuryu
	著者名 Monden, Chikako
	著者名 Kamimura, Taro
	著者名 Hayashi, Terumasa
	NRID 1000070393220 1000070393220 著者名 Yoshihara, Fumiki
	NRID 1000000379166 1000000379166 ORCID 0000-0002-0820-7167 0000-0002-0820-7167 researchmap permalink isaka-handai3857 isaka-handai3857 Scopus Author ID 16207611100 16207611100 著者名 Isaka, Yoshitaka
キーワード等	peritoneal dialysis
	SGLT2 inhibitor
	ultrafiltration
内容	Doi Y., Shinzawa M., Arisato T., et al. Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis. Kidney International Reports 11, 141 (2025); https://doi.org/10.1016/j.ekir.2025.09.049 .
抄録	Introduction: Sodium-glucose cotransporter 2 (SGLT2) is expressed in the human peritoneum, and preclinical studies suggest that SGLT2 inhibitors may enhance ultrafiltration by reducing glucose absorption from peritoneal dialysis (PD) solutions. This study evaluated whether empagliflozin increases ultrafiltration volume (UFV) in patients on PD. Methods: In this multicenter, randomized (1:1), double-blind, placebo-controlled crossover trial, patients on PD received empagliflozin (10 mg/d) or placebo for 8 weeks, separated by a 4-week washout period. The primary outcome was the change in daily UFV from baseline to week 8 in each treatment period. Results: Of 40 randomized patients, 37 received treatment and were analyzed. The median age was 66 years, PD duration was 2.8 years, and 46% were female. At baseline, median daily UFV was 476 ml with 4500 ml of glucose-based dialysate. At week 8, change in UFV did not significantly differ between treatments (−38 ml; 95% confidence interval [CI]: −120 to 44; P = 0.36). No heterogeneity was observed in subgroups by diabetes or peritoneal membrane transport characteristics. Empagliflozin had no significant effect on UFV or dialysate glucose or sodium concentrations, assessed by peritoneal equilibration test (PET). Urinary glucose excretion increased by 2698 mg/d (95% CI: 343–5052), without changes in urine volume, sodium, or protein excretion. Adverse events occurred in 47% with empagliflozin and 29% with placebo; serious adverse events occurred in 11% and 6%, respectively. Conclusion: Empagliflozin did not significantly improve UFV in patients on PD, suggesting limited short-term clinical utility.
出版者	Elsevier Inc.
収録物名	Kidney International Reports
巻(号)	11(1)
ページ	141-151
刊行年月	2025-12-23
言語	英語
ハンドルURL	https://hdl.handle.net/11094/103674
PISSN	24680249
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1016/j.ekir.2025.09.049
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Kidney International Reports. 2025, 11(1), p. 141-151
DC.title	Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis
DC.creator	Doi, Yohei
	Shinzawa, Maki
	Arisato, Tetsuya
	Oka, Hideaki
	Ueda, Yoshiyasu
	Matsumoto, Ayumi
	Kitamura, Harumi
	Hamano, Takayuki
	Nakazono, Yumi
	Nishiya, Yoichi
	Hashimoto, Nobuhiro
	Matsuo, Miki
	Sonoura, Takuryu
	Monden, Chikako
	Kamimura, Taro
	Hayashi, Terumasa
	Yoshihara, Fumiki
	Isaka, Yoshitaka
DC.publisher	Elsevier Inc.
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-12-23
DC.identifier	https://doi.org/10.1016/j.ekir.2025.09.049
DC.subject	peritoneal dialysis
	SGLT2 inhibitor
	ultrafiltration
DC.description	Doi Y., Shinzawa M., Arisato T., et al. Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis. Kidney International Reports 11, 141 (2025); https://doi.org/10.1016/j.ekir.2025.09.049 .
DCTERMS.abstract	Introduction: Sodium-glucose cotransporter 2 (SGLT2) is expressed in the human peritoneum, and preclinical studies suggest that SGLT2 inhibitors may enhance ultrafiltration by reducing glucose absorption from peritoneal dialysis (PD) solutions. This study evaluated whether empagliflozin increases ultrafiltration volume (UFV) in patients on PD. Methods: In this multicenter, randomized (1:1), double-blind, placebo-controlled crossover trial, patients on PD received empagliflozin (10 mg/d) or placebo for 8 weeks, separated by a 4-week washout period. The primary outcome was the change in daily UFV from baseline to week 8 in each treatment period. Results: Of 40 randomized patients, 37 received treatment and were analyzed. The median age was 66 years, PD duration was 2.8 years, and 46% were female. At baseline, median daily UFV was 476 ml with 4500 ml of glucose-based dialysate. At week 8, change in UFV did not significantly differ between treatments (−38 ml; 95% confidence interval [CI]: −120 to 44; P = 0.36). No heterogeneity was observed in subgroups by diabetes or peritoneal membrane transport characteristics. Empagliflozin had no significant effect on UFV or dialysate glucose or sodium concentrations, assessed by peritoneal equilibration test (PET). Urinary glucose excretion increased by 2698 mg/d (95% CI: 343–5052), without changes in urine volume, sodium, or protein excretion. Adverse events occurred in 47% with empagliflozin and 29% with placebo; serious adverse events occurred in 11% and 6%, respectively. Conclusion: Empagliflozin did not significantly improve UFV in patients on PD, suggesting limited short-term clinical utility.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	103674
citation_title	Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis
citation_author	Doi, Yohei
	Shinzawa, Maki
	Arisato, Tetsuya
	Oka, Hideaki
	Ueda, Yoshiyasu
	Matsumoto, Ayumi
	Kitamura, Harumi
	Hamano, Takayuki
	Nakazono, Yumi
	Nishiya, Yoichi
	Hashimoto, Nobuhiro
	Matsuo, Miki
	Sonoura, Takuryu
	Monden, Chikako
	Kamimura, Taro
	Hayashi, Terumasa
	Yoshihara, Fumiki
	Isaka, Yoshitaka
citation_publisher	Elsevier Inc.
citation_language	英語
citation_date	2025-12-23
citation_journal_title	Kidney International Reports
citation_volume	11
citation_issue	1
citation_firstpage	141
citation_lastpage	151
citation_doi	https://doi.org/10.1016/j.ekir.2025.09.049
citation_public_url	https://hdl.handle.net/11094/103674

Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis

閲覧可能ファイル

論文情報

論文詳細を表示